Fig. 4: Leydig cells and Sertoli cells are permissive to trVLP entry and transcription.

A Quantification of VP40 gene copies in Leydig cells treated with EBOV trVLP. B Luminescence of the firefly luciferase reporter in mock-treated and EBOV trVLP-treated Leydig cells. C Quantitation of VP40 gene copies in Sertoli cells treated with EBOV trVLP. D Luminescence of the firefly luciferase reporter in mock-treated and EBOV trVLP-treated Sertoli cells. For each time point, EBOV VP40 RNA and luciferase luminescence was quantified based on three biological replicates and two technical replicates. Primer sequences for strand-specific RNA reverse transcription and quantitation of viral VP40 are listed in Table 1. Significant differences in firefly luciferase luminescence between mock-treated and EBOV trVLP-treated cells was determined using 2-way ANOVA. Significant changes in quantity of EBOV VP40 between neighboring time points were determined using the Student’s t test. Asterisks indicate a significant difference, where *, **, ***, and **** indicates that P ≤ 0.05, P ≤ 0.01, P ≤ 0.001, and P ≤ 0.0001, respectively.